Alvaro J. Alencar, MD

Associate Professor of Clinical Medicine
University of Miami Sylvester Comprehensive Cancer Center

Poster(s):

• 1506 - Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory CLL: updated findings from an ongoing Phase 1a study

• 1512 - Pirtobrutinib after a Covalent BTK Inhibitor in Pretreated Chronic Lymphocytic Leukemia: A Phase 2 Dose Optimization Trial in Progress